Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00408252
Other study ID # GORTEC 2006-01
Secondary ID IIR Study A61810
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 2007
Est. completion date December 2011

Study information

Verified date September 2019
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So at the light of these pre-clinical and clinical data, it seems interesting and promising to test SU011248 in these poor prognosis patients.


Description:

This is an open-label phase II, multicenter study. Eligible patients will receive SU011248 in monotherapy (37.5 mg given continuously without interruption). Tumor check-up will be performed every 6-8 weeks. Treatment will be continued until disease progression or unacceptable toxicities according to the patient or the investigator (the median for treatment in renal cell study was 8 months).

Since, head and neck tumors are easily accessible for iterative biopsy, this study will offer the opportunity to get tumor biopsies before and after SU011248. Our study will allow translational research with biopsies at crucial timing: at baseline before any treatment, , during the treatment with SU011248 (cycle 1, between week 4 and 6), for patients with stable disease or partial response, a new biopsy will be performed at the time of disease progression to try to understand the mechanisms of tumor or resistance.


Recruitment information / eligibility

Status Terminated
Enrollment 54
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation

- Recurrence must be confirmed by anatomopathology (cytology or biopsy)

- At least one measurable lesion by MRI or CT-scan

- Failed or relapsing after first line chemotherapy including a platinum* or a taxane-based chemotherapy regimen

- Patients ineligible for chemotherapy could be included in first line

- ECOG performance status 0 -2, in stable medical condition

- Patients must be able to swallow tablets

- Patients must have an expected survival of at least 3 months

- Paraffin-embedded tumor tissue available for immunohistochemistry

- Patients must be over 18 years old and must be able to give written informed consent

- Women of child-bearing age must have a negative pregnancy test

- Female patients of child-bearing age must use effective contraception until 3 months have elapsed after the last injection

- Patients must have normal organ function

- For patients with local recurrence and easily accessible tumors, acceptance of iterative biopsies to store tumor samples (Formaldehyde for immunochemistry, RNA later)

- Acceptance of giving 20 ml of blood for eventual pharmacogenomic analysis

- Acceptance of giving two plasma samples (3ml) at baseline and after 4 weeks of treatment with SU011248

- Signed informed consent prior to beginning protocol specific procedure

Exclusion Criteria:

- Non-squamous head and neck cancer

- Nasopharynx cancer

- Brain metastases

- More than two lines of chemotherapy for palliative treatment (except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)

- Surgery or irradiation or investigational drugs within 4 weeks before study inclusion

- Other uncontrolled illnesses (active infections requiring antibiotics, bleeding disorders, …)

- Active uncontrolled coronary disease or cardiac insufficiency (Ejection fraction below 40%)

- Previous malignancy, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

- Other concomitant anticancer therapies

- Previous treatment with anti-VEGF, PDGF, or kit therapies. EGFR therapy is not an exclusion criteria.

- Organic brain syndrome or significant psychiatric abnormality that would preclude participation in the full protocol and follow up.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
biopsies
No intervention, only biopsy for translational project
Drug:
SU011248
no intervention

Locations

Country Name City State
Belgium Cliniques Universiatires St LUC UCL Bruxelles
Belgium clinique Sainte Elisabeth Namur
Belgium Clinique universiataire de Mont Godinnes UCL Yvoir
France Centre Jean Perrin Clermont Ferrand
France Centre G-f Leclerc DIJON Cedex
France Centre Alexis Vautrin Nancy
France René Gauducheau Saint Herblain Cedex
France CHU Bretonneau Tours cedex 1
France Institut Gustave Roussy Villejuif Cedex

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the efficacy of SU011248 alone in patients with head and neck cancer in term of overall response rate (RECIST, see statistical consideration) every 6 weeks
Secondary Determine the safety profile of SU011248 alone in patients with head and neck cancer. untill disaese progression
Secondary Determine the efficacy of SU011248 alone in patients with head and neck cancer: progression-free survival and survival. untill disease progression
Secondary Translational research objective:To better understand the mechanisms of sunitinib resistance by the analysis of the tumor biopsies (RNA, gene expression profile) and protein profile (plasma samples). Exploratory analyses. at week 6 and at disaese progression after recist response
See also
  Status Clinical Trial Phase
Completed NCT02204761 - Proton Beam Re-Irradiation in Thoracic Cancers N/A
Completed NCT01445080 - Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Phase 1/Phase 2
Terminated NCT03525392 - Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. Phase 1
Completed NCT01794845 - Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma Phase 2
Completed NCT02210858 - Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Phase 1/Phase 2
Recruiting NCT05432518 - Pilot Trial for Treatment of Recurrent Glioblastoma Early Phase 1
Completed NCT00351975 - Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Phase 1
Completed NCT03060096 - Stepped-Care Telehealth for Distress in Cancer Survivors N/A
Not yet recruiting NCT03591666 - A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas Phase 2
Completed NCT00036738 - Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib Phase 2
Recruiting NCT05260671 - Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN Phase 2
Completed NCT01737450 - Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Phase 2
Completed NCT03415477 - Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Phase 1/Phase 2
Recruiting NCT06088719 - Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence
Terminated NCT02488512 - Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas Phase 2
Recruiting NCT02747732 - Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL Phase 2
Completed NCT00383474 - Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Phase 1
Completed NCT00003145 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia Phase 2
Recruiting NCT06014619 - Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
Active, not recruiting NCT03792256 - Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) Phase 1